Soufflé Therapeutics raised $135 million in VC funding to advance at least three experimental oligonucleotide medicines. The Bob Langer-affiliated startup said the capital is intended to move multiple RNA programs forward, reflecting the sector’s ongoing focus on multiple assets rather than single-lead bets. The round reinforces investor interest in oligonucleotide modalities—especially those designed to improve delivery, tissue targeting, and manufacturability at scale. For biotech, the funding supports continued competition among RNA medicine startups seeking to convert early pharmacology into clinical-stage differentiation.